Jan 11, 2023 / 10:15PM GMT
Luka Kachukhashvili -
Hi, everyone. Welcome to the third day of the JPMorgan Healthcare Conference. My name is Luka Kachukhashvili. I'm an associate here in health care investment banking team. It's my absolute pleasure to welcome AbCellera Biologics. Joining us is Carl Hansen, Chairman, CEO and President. And with that, handing it off to you, Carl.
Carl L.G. Hansen - AbCellera Biologics Inc. - CEO, President & Chairperson
Thanks very much, Luka, and thank you to JPMorgan for inviting us to participate this year. It's actually our first time at JPMorgan. And I think, like others here, I could express that it's terrific to be back in person, meeting people and feeling the energy of the sector.
So before I begin, I just want to draw everyone's attention to our disclaimer about forward-looking statements. Please look at our filings with respect to that. And with that, get into the presentation.
So AbCellera was founded about a decade ago in 2012 to take on a big, ambitious and bold company-building and technology development project, basically to try
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot